FDA expands use of Regeneron's HoFH drug Evkeeza to kids 5 and up

[cafead]

via One day after gaining a pediatric approval in Europe for Dupixent, Regeneron has earned an FDA nod for the use of Evkeeza in children ages 5 through 11 with homozygous familial hypercholesterolemia (HoFH).

article source